Treatment and Prognostic Factors for Survival in Newly Diagnosed Multiple Myeloma Patients with Bortezomib and Dexamethasone Regimen: a Single Chinese Center Retrospective Study

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2017 Sep 9

PMID 28883741

Citations 2

Authors

Runzhe Chen

Xiaoping Zhang

Chong Gao

ChengXin Luan

Yujie Wang

Baoan Chen

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this retrospective study was to evaluate the efficacy and prognostic factors of bortezomib and dexamethasone (BD) chemotherapy regimen in the treatment of newly diagnosed multiple myeloma (MM) patients in our hospital.

Methods: A total of 47 newly diagnosed MM patients treated in our hospital from May 2010 to September 2016 were included in this study. All the enrolled patients received at least two cycles of BD chemotherapy regimen.

Results: The overall response rate after treatment was 68.5% with a complete response of 23.4%, very good partial response of 17.0%, partial response of 21.3% and minor response of 6.8%. The median time of overall survival (OS), progression-free survival (PFS) and time to progression (TTP) of the treated patients were 36.0, 19.0 and 18.0 months, respectively; the mean OS, PFS and TTP were 36.0, 19.3 and 18.8 months, respectively. Though some adverse events had occurred, none of the patients was discontinued from treatment. Level of albumin, β-microglobulin and cytogenetic abnormalities were prognostic factors for OS, and plasma cell percentage in bone marrow, β-microglobulin and cytogenetic abnormalities were prognostic factors for PFS as revealed by log-rank test of univariate analysis; no prognostic factors for OS and PFS were detected by COX regression of multivariate analysis.

Conclusion: Our study demonstrated that BD regimen was effective and well tolerated in newly diagnosed MM patients, and prognostic factors for patients' survival include level of albumin, plasma cell percentage in bone marrow, β-microglobulin and cytogenetic abnormalities.

Citing Articles

Construction of a prognosis‑associated long noncoding RNA‑mRNA network for multiple myeloma based on microarray and bioinformatics analysis.

Zhu F, Wang X, Ye Z, Gan Z, Lai Y Mol Med Rep. 2020; 21(3):999-1010.

PMID: 32016443 PMC: 7003030. DOI: 10.3892/mmr.2020.10930.

Upregulation of lncRNA NR_046683 Serves as a Prognostic Biomarker and Potential Drug Target for Multiple Myeloma.

Dong H, Jiang S, Fu Y, Luo Y, Gui R, Liu J Front Pharmacol. 2019; 10:45.

PMID: 30766487 PMC: 6365438. DOI: 10.3389/fphar.2019.00045.

References

Zwickl H, Zwickl-Traxler E, Pecherstorfer M . A single-center retrospective analysis of first-line therapy of multiple myeloma with bendamustine-bortezomib-dexamethasone. Leuk Lymphoma. 2016; 57(9):2065-70. DOI: 10.3109/10428194.2015.1126587. View

Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta J, Cavo M . Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013; 31(26):3279-87. DOI: 10.1200/JCO.2012.48.4626. View

Chen R, Tu Y, Cao Y, Liu L, Liang Y . Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients. J Int Med Res. 2011; 39(5):1975-84. DOI: 10.1177/147323001103900544. View

Li F, Xu Y, Deng P, Yang Y, Sui W, Jin F . Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. Oncotarget. 2015; 6(11):9434-44. PMC: 4496228. DOI: 10.18632/oncotarget.3319. View

Sonneveld P, Schmidt-Wolf I, van der Holt B, El Jarari L, Bertsch U, Salwender H . Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012; 30(24):2946-55. DOI: 10.1200/JCO.2011.39.6820. View

Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F . Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008; 111(8):3968-77. DOI: 10.1182/blood-2007-10-117457. View

Shaughnessy Jr J, Qu P, Usmani S, Heuck C, Zhang Q, Zhou Y . Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood. 2011; 118(13):3512-24. PMC: 3186329. DOI: 10.1182/blood-2010-12-328252. View

Mohty M, Malard F, Mohty B, Savani B, Moreau P, Terpos E . The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer. 2013; 120(5):618-23. DOI: 10.1002/cncr.28481. View

Guo H, Zhou X, Jiang Y, Yang G, Sun C, Zhuang Y . Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience. Am J Hematol. 2010; 85(7):499-501. DOI: 10.1002/ajh.21734. View

10.

Liu X, He C, Meng X, He L, Li K, Liang Q . Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials. Onco Targets Ther. 2015; 8:1459-69. PMC: 4474400. DOI: 10.2147/OTT.S84828. View

11.

Zeng W, Meng F, Liu Z, Mao X, Luo L, Zheng M . Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. Int J Clin Exp Pathol. 2014; 7(7):4239-46. PMC: 4129039. View

12.

Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E . Treatment of multiple myeloma. Blood. 2003; 103(1):20-32. DOI: 10.1182/blood-2003-04-1045. View

13.

Bianchi G, Munshi N . Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015; 125(20):3049-58. PMC: 4432002. DOI: 10.1182/blood-2014-11-568881. View

14.

Cejalvo M, Rubia J . Clinical treatment of newly diagnosed multiple myeloma. Expert Rev Hematol. 2015; 8(5):595-611. DOI: 10.1586/17474086.2015.1078236. View

15.

San Miguel J . Introduction to a series of reviews on multiple myeloma. Blood. 2015; 125(20):3039-40. DOI: 10.1182/blood-2015-01-613596. View

16.

Chen R, Wang Y, Luan C, Gao C, Zhang X, Chen B . Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. J Cancer. 2017; 8(10):1801-1808. PMC: 5556643. DOI: 10.7150/jca.17999. View

17.

Lu J, Chen W, Huo Y, Huang X, Hou J . Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014; 4:e239. PMC: 4219472. DOI: 10.1038/bcj.2014.55. View

18.

Aguiar P, Lima T, Colleoni G, Storpirtis S . Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. Crit Rev Oncol Hematol. 2017; 113:195-212. DOI: 10.1016/j.critrevonc.2017.03.014. View

19.

Barlogie B, Epstein J, Selvanayagam P, Alexanian R . Plasma cell myeloma--new biological insights and advances in therapy. Blood. 1989; 73(4):865-79. View

20.

Chen R, Chen B, Zhang X, Gao C . Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials. Discov Med. 2016; 22(121):189-199. View